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Abstract
Objective To study the pharmacokinetics of micafungin in
intensive care patients and assess pharmacokinetic (PK)
target attainment for various dosing strategies.
Methods Micafungin PK data from 20 intensive care unit
patients were available. A population-PK model was
developed. Various dosing regimens were simulated:
licensed regimens (I) 100 mg daily; (II) 100 mg daily with
200 mg from day 5; and adapted regimens 200 mg on day
1 followed by (III) 100 mg daily; (IV) 150 mg daily; and
(V) 200 mg daily. Target attainment based on a clinical PK
target for Candida as well as non-Candida parapsilosis
infections was assessed for relevant minimum inhibitory
concentrations [MICs] (Clinical and Laboratory Standards
Institute). Parameter uncertainty was taken into account in
simulations.
Results A two-compartment model best fitted the data.
Clearance was 1.10 (root square error 8%) L/h and V1 and
V2 were 17.6 (root square error 14%) and 3.63 (root square
error 8%) L, respectively. Median area under the concen-
tration–time curve over 24 h (interquartile range) on day
14 for regimens I–V were 91 (67–122), 183 (135–244), 91
(67–122), 137 (101–183) and 183 (135–244) mg h/L,
respectively, for a typical patient of 70 kg. For the MIC/
area under the concentration–time curve[3000 target (all
Candida spp.), PK target attainment was[91% on day 14
(MIC 0.016 mg/L epidemiological cut-off) for all of the
dosing regimens but decreased to (I) 44%, (II) 91%, (III)
44%, (IV) 78% and (V) 91% for MIC 0.032 mg/L. For the
MIC/area under the concentration–time curve[5000 target
(non-C. parapsilosis spp.), PK target attainment varied
between 62 and 96% on day 14 for MIC 0.016.
Conclusions The licensed micafungin maintenance dose
results in adequate exposure based on our simulations with
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a clinical PK target for Candida infections but only 62% of
patients reach the target for non-C. parapsilosis. In the case
of pathogens with an attenuated micafungin MIC, patients
may benefit from dose escalation to 200 mg daily. This
encourages future study.
Key Points
A population pharmacokinetic model of micafungin
in critically ill patients greatly assists in applying
simulations to derive pharmacokinetic target
attainment.
Current micafungin dosing regimens are adequate to
treat Candida infections with species up to
0.016 mg/L but the dose should be increased to
200 mg in the case of minimum inhibitory
concentrations C0.032 mg/L.
Irrespective of the susceptibility of the species, a
loading dose will lead to early higher exposure.
1 Introduction
Candida or Aspergillus species are the fourth most domi-
nant pathogens causing disease complication in the inten-
sive care unit (ICU) and account for approximately 20% of
infections in the ICU [1, 2]. Micafungin is an antifungal
agent belonging to the class of echinocandins that act by
inhibiting the synthesis of b-(1,3)-D-glucan, an important
component of the fungal cell wall. It is a semi-synthetic
compound, freely soluble in water and it has a molecular
weight of 1292.26 [3, 4]. Micafungin shows in vitro and
in vivo activity against Candida species and it is licensed
as a first-line treatment for invasive candidiasis [3–5].
Micafungin, like other echinocandins, achieves adequate
clinical responses in about 70% of patients with invasive
candidiasis or candidaemia [2, 6].
The recommended micafungin dose is a daily (QD)
intravenous infusions of 100 mg (infusion time approxi-
mately 1 h) [4]. In the case of insufficient response, such as
when the clinical condition does not improve or in case of
persistent positive cultures, the dose may be increased to
200 mg QD [4].
Recently, we analysed the pharmacokinetics of mica-
fungin in 20 critically ill patients (ICU patients) by means
of a non-compartmental approach [7]. A lower total
exposure [area under the concentration–time curve over
24 h (AUC0–24h)] was observed in this cohort as compared
with healthy volunteers, although the total exposure was
comparable to other patient populations [7].
The pharmacodynamic (PD) index of the echinocandins
is best described by the area under the concentration–time
curve:minimum inhibitory concentration (AUC:MIC) ratio
[8, 9]. To design optimal dosing regimens for micafungin
in critically ill patients, both pharmacokinetic (PK) and PD
factors need to be incorporated into a model. A non-com-
partmental analysis is not sufficient for the purpose of
modelling and simulations. Hence, we will deploy an
additional PK-PD analysis using non-linear mixed-effect
modelling to obtain a further understanding of the phar-
macokinetics of micafungin. Defining such a PK model
will enable us to simulate different dosing regimens and
assess the corresponding exposure (AUC) and PK target
attainment, taking into account the susceptibility profiles of
the pathogen.
Micafungin clinical breakpoints have been defined in a
phase III clinical study among patients with invasive can-
didiasis. An AUC:MIC between 3000 and 12,000 was
associated with 98% success for all Candida species. A
specific target was defined of an AUC:MIC ratio of
5000:12,000 for non C. parapsilosis species and above 285
for C. parapsilosis [10]. Micafungin has an overall
favourable safety profile; therapy with 150–200 mg QD is
well tolerated [3].
We aimed to combine our PK data and the clinical
breakpoints data to determine the probability of target
attainment (PTA) in a population of critically ill patients.
This will enable us to make simulations for other regimens
to investigate the gain in the PTA in pathogens with altered
susceptibility profiles.
2 Materials and Methods
2.1 Ethics
This study was conducted in compliance with the Decla-
ration of Helsinki and approved by the local medical ethics
committee (Commissie Mensgebonden Onderzoek region
Arnhem-Nijmegen number, clinical trials.gov
NCT01783379). Informed consent was given by all
participants.
2.2 Study Design, Drug Regimen and Population
All data were collected in a prospective PK study published
previously [7]. Patients admitted to the ICU and receiving
micafungin for suspected or proven fungal infection were
eligible if they met the following inclusion criteria:
C18 years of age on the day of the first micafungin dose,
not receiving micafungin treatment for [2 days before
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enrolment and having an indwelling central venous or
arterial catheter. Exclusion criteria included patients with a
history of hypersensitivity to echinocandins or excipients
similar to those found in the micafungin preparation,
human immunodeficiency virus or hepatitis B/C infection,
or abuse of alcohol or drugs. All participants received
micafungin 100 mg QD. Micafungin was administered
intravenously over approximately 1 h. Micafungin therapy
was continued as long as was considered clinically indi-
cated, but the duration of the study was limited to a max-
imum of 14 days with an additional 3 days after the end of
therapy.
Demographic information was gathered and included
age, sex, race, weight (available from the medical record
previous to ICU admission, estimated or weighted on the
ICU), height, relevant co-medication, indication for mica-
fungin use, clinical characteristics, chemistry and haema-
tological parameters. In addition, Acute Physiology and
Chronic Health Evaluation II, Sequential Organ Failure
Assessment (SOFA), Child-Pugh score and (type of) renal
replacement therapy were recorded.
2.3 Pharmacokinetic Sampling and Analysis
At day 3 (±1) patients were intensively sampled (2 mL) at
t = 0 (pre-dose) and 0.5, 1, 2, 4, 6, 8, 12, 18 and 24 h post
start infusion during a dosing interval. At day 7 (±1), a
second PK curve of six samples was drawn at t = 0, (pre-
dose) and 1, 4, 8, 12 and 24 h post start infusion. Addi-
tional daily trough concentrations were drawn daily until
3 days after cessation of micafungin therapy. A validated
ultra-performance liquid chromatography-fluorescence
assay was used to analyse the samples, details have been
described previously [7].
2.4 Pharmacokinetic Model
Population PK analysis of micafungin was performed with
non-linear mixed-effects modelling using the first-order
conditional estimation method with interaction between
random effects and residual variability as implemented in
NONMEM (version 7.3; ICON Development Solutions,
Ellicott City, MD, USA) [11]. Pirana interface (PiranaJS,
version 1.01) (Pirana Software & Consulting BV 2016,
Amsterdam, The Netherlands) [12, 13] was used as an
interface for NONMEM, Perl-Speaks-NONMEM (version
4.2.0), Xpose (version 4.5.3) and R (version 3.2.1) [14].
As body weight (BW) is a known confounder for
pharmacokinetics, the impact of BW on the pharmacoki-
netics of micafungin were accounted for by allometric
scaling, as proposed previously, with an allometric expo-
nent of 0.75 for all flow parameters and an exponent of 1
for all volume parameters standardised to a 70-kg patient as
proposed previously [15–18]. One-, two- and three-com-
partment models were considered to describe the drug
disposition. The primary PK parameters were clearance
(CL) and volume of distribution (V). Inter-individual
variability (IIV) and inter-occasion variability (IOV) was
estimated using an exponential model. Residual variability
was evaluated by proportional, additive and combined
additive, and proportional models. Inter-individual random
effects were evaluated with a single covariance matrix on
the parameters of the first compartment as well as with a
full covariance matrix on the parameters of all compart-
ments. IOV was considered on CL and V. Structural model
selection was guided by objective function value (OFV) as
computed by NONMEM, corresponding to minus twice the
log-likelihood (a D of -3.84 with 1 degree of freedom,
Chi-squared distribution, corresponds to a significance
level of p = 0.05) goodness-of-fit plots and physiological
plausibility. In addition, the precision of the parameter
estimates, ETA shrinkage, and IIV and IOV were assessed,
as well as parameter correlation. Candidate models were
further evaluated by a prediction-corrected visual predic-
tive check (n = 1000 simulations) and a numerical pre-
dictive check based on n = 1000 simulations [19]. With
the visual predictive check, the observed data were com-
pared with the model-simulated data to evaluate the
internal validity of the model.
After selection of the base model, the following
covariates were tested on CL and V based on physiolog-
ical plausibility: albumin, Continuous Veno-Venous
Hemofiltration (CVVH) and SOFA. The effect of albumin
was assessed on V1 and CL. The effect of CVVH was
assessed on V1 (dichotomous covariate). SOFA scores
were obtained on different days. Missing values of non-
sampling days before the observation were replaced by
the first value (usually at 48 h) and missing values after
observations were carried forward. In the case of com-
pletely missing SOFA scores, the median of 7 was used.
The SOFA score was divided into a low score (\10) and a
high score ([10) based on associated mortality risks
[20, 21] and was assessed as a categorical covariate on CL
and V.
Covariates were tested in a stepwise fashion (forward
inclusion, backward elimination). A covariate was included
when it was physiologically plausible and the OFV
decreased with 3.84 points (Chi-squared distribution,
p = 0.05). The precision of the parameter estimates was
assessed using a non-parametric bootstrap method in which
resampling of the data to create new datasets with the same
size but containing different sets of individuals and yield-
ing new parameter estimates and confidence intervals
occurred (n = 1000 replications).
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2.5 Monte-Carlo Simulations of Pharmacokinetics
and Target Attainment with Various Dosing
Regimens
The final model was used to perform a simulation study
exploring various dosing regimens. As the ICU cohort used
for model building was considered too small for simulation
purposes (n = 20), a cohort of 1000 hypothetical individ-
uals with a mean BW of 70 kg with 20% coefficient of
variation (CV) in BW was generated for each dosing reg-
imen. This variation in weight (20% CV) was based on the
weight distribution of a haematological cohort from our
hospital (n = 1706, median 76.4 kg and standard deviation
14.5, resulting in 18.96% CV). Simulations were per-
formed also propagating parameter uncertainty, with the
TNPRI function in NONMEM, using priors from the final
model.
Five dosing regimens were simulated including licensed
regimens and alternative regimens, chosen at the discretion
of the researchers. Licensed regimens included (I) 100 mg
QD for 14 days and (II) 100 mg QD the first 4 days with
200 mg QD from day 5 (labelled indication for non-re-
sponders); alternative regimens included (III) 200-mg
loading dose on day 1 followed by 100 mg QD from day 2,
(IV) 200-mg loading dose followed by 150 mg QD from
day 2 and (V) 200 mg QD. A 200-mg dose is not expected
to be associated with toxicity as micafungin doses of 8 mg/
kg are well tolerated [4].
2.6 Probability of Target Attainment
The PK-PD target for micafungin in the treatment of
invasive candidiasis was determined by the group of Andes
et al. [10]. The exposure-response relationship of mica-
fungin has been well established: an AUC/MIC ratio of
3000:12,000 has previously been associated with a 98%
mycological response for all Candida infections, while a
target of 5000:12,000 has been associated with a 97.8%
mycological response for non-C. parapsilosis infections
[10]. We used both an AUC/MIC ratio of[ 3000 well as
5000 as the PK-PD target for the simulations. Furthermore,
the model presented will allow other researchers to use our
PK model for simulations on different Candida species
whenever needed. However, this is beyond the scope of
this article as the focus is on PK variability in a population
of critically ill patients.
Target attainment at days 3 and 14 was assessed for a
range of clinically relevant MIC values (0.002–1 mg/L) of
the Clinical and Laboratory Standards Institute. This range
includes both the modal MIC for micafungin for C. albi-
cans (0.015 mg/L) as the epidemiological cut-off MIC
(0.03 mg/L, Clinical and Laboratory Standards Institute
reference method) [22, 23].
2.7 Minimum Inhibitory Concentration
Distribution
In addition to the determination of the PTA for each
individual MIC, the PTA considering the population dis-
tribution was evaluated. For each MIC, the fraction of
simulated patients who attained the PK target was multi-
plied by the fraction of the MIC distribution of C. albicans.
The cumulative fraction of response was calculated as the
sum of fraction products over all MICs. The population
distribution of C. albicans was gathered from Pfaller et al.,
as this species is often involved in candidaemia in ICU
patients [22].
3 Results
3.1 Patients, Dosing and Samples
Twenty patients completed the first PK curve on day 3 and
were eligible for analysis. A total of 356 time-concentra-
tion observations were available to build the model.
Baseline patient characteristics are summarised in Table 1.
Median age was 68 years (range 20–84 years) and median
BW was 77 kg (range 50–134 kg). All patients had pro-
nounced hypoalbuminaemia (serum albumin B34 g/L). All
patients received micafungin 100 mg QD. No dose adap-
tations were performed [7].
3.2 Population Pharmacokinetic Model
A two-compartment disposition model with first-order
elimination from the central compartment and a propor-
tional residual error model fitted the data best. IIV on CL
and V1 further improved the model while data did not
support the addition of IIV on Q or V2. Allowing a corre-
lation between IIV of CL and V1 further improved the
model (difference OFV = 13.98). High IOV on V1 was
observed, indicating important variation in V1 from day to
day within this population. Parameter estimates of the
model are shown in Table 2. CL, V1, Q and V2 were esti-
mated to be 1.10 L/h, 17.6 L, 0.363 L/h and 3.63 L. The
IIV on CL and V1 were estimated to be 40 and 73% CV
with ETA shrinkage of 1.2 and 41%, respectively, while
IOV on V1 was estimated to be 37% CV. No covariates
were identified to significantly affect CL or V1.
Basic goodness-of-fit plots are shown in the supple-
mentary file (Fig. S1). The plots did not show major
deviations. A prediction-corrected visual predictive check
of the final model is shown in the supplementary file
(Fig. S2). Predictions were consistent with the observa-
tions, suggesting a good validity of the model to the data.
The numerical predictive check showed that 0.9% (95%
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confidence interval 0–6.8%) of observations fell below the
95% prediction interval and 2.0% (95% confidence interval
0–8.8%) fell above the 95% prediction interval. Parameter
precision was assessed using a bootstrap re-sampling
approach of the final model, the results of which are listed
in Table 2.
3.3 Monte-Carlo Simulations of Alternative Dosing
Regimens
Monte-Carlo simulations were performed to assess daily
exposure (AUC0–24h) obtained with licensed and alterna-
tive dosing regimens. AUC0–24h values on day 14 of ther-
apy are shown in Fig. 1. Median (interquartile range)
AUC0–24h values on day 3 for the five regimens (I–V) were
86 (62–116), 86 (62–116), 92 (66–125), 132 (95–180) and
172 (124–232) mg h/L and on day 14 were 91 (67–122),
183 (135–244), 91 (67–122), 137 (101–183) and 183
(135–244) mg h/L, respectively.
Simulated plasma concentration–time profiles of the first
week of therapy in a typical patient weighing 70 kg fol-
lowing the different dosing regimens are shown in the
supplementary file (Fig. S3). Administration of a loading
dose resulted in higher exposure early in therapy (regimens
III–IV).
3.4 Pharmacokinetic Target Attainment
The PTA on day 3 of therapy based on the Monte-Carlo
simulations are shown in Figs. 2 and 3. As can be expected,
the PTA increased with increasing doses and decreased
with higher MIC values. For example, adding a loading
dose together with increasing the maintenance dose to
150–200 mg QD led to increased target attainment: B46 vs.
[74% on day 3 for a micafungin MIC of 0.032 mg/L for
the target of[3000.
The main differences in the PTA between days 3 and 14
are observed for regimen II, as with this regimen the
maintenance dose is increased from 100 to 200 mg on day
5 of therapy. The PTA for all simulated regimens is also
given as a supplementary file (Supplementary Tables 1, 2).
Table 3 shows the results of the PTA integrated with the
distribution of the MIC for C. albicans and non-C. para-
psilosis, resulting in the cumulative fraction of the pre-
dicted response. Higher maintenance dose (regimens II, IV
and V) resulted in a higher cumulative PTA.
4 Discussion
We developed a population PK model for micafungin in
ICU patients. The model was successfully used to assess
different dosing regimens of micafungin to predict the
corresponding PTA, taking into account parameter uncer-
tainty. The simulations revealed that the majority of the
population is treated sufficiently with the current licensed
dosing regimen, but the PTA for infections with Candida
species with a MIC of 0.032 mg/L can be improved by
increasing the maintenance dose a priori to 200 mg.
Clearance in our cohort was 1.10 L/h and modestly
higher compared with CL in healthy volunteers [24, 25].
Three population PK models have been published previ-
ously. Clearance in our cohort was similar to ICU patients
on CVVH, mechanical ventilation or with an intra-ab-
dominal infection [26–29]. Inter-individual variability on
CL was 40% CV in our cohort and therefore higher than
observed in healthy volunteers [24] or ICU patients on
CVVH (17–20% CV) [26] but similar to ICU patients with
sepsis and mechanical ventilation (34%) [29]. Volume of
distribution was higher than in healthy volunteers (13.3 L
Table 1 Patient demographics of the ICU cohort used to develop the
population pharmacokinetic model
Demographics Evaluable ICU patients (n = 20)
Female, n (%) 12 (60)
Age (years), median (range) 68 (20–84)
Weight (kg), median (range) 76.5 (50–134)
BMI (kg/m2), median (range) 24.6 (16.3–47.5)
Clinical characteristics (at baseline)
Renal replacement therapy, n (%)
CVVH 5 (25)
Intermittent hemodialysis 1 (5)
Neutropenia 0 (0)
Hypoalbuminemia, n (%)
25–34 g/L 2 (10)
15–24 g/L 13 (65)
\15 g/L 5 (25)
Infection location, n (%)
Blood 3 (15)
Other 20 (100)
Species, n (%) 1 (5)
Candida spp. 20 (100)
C. albicans 11 (55)
Non-albicans 11 (55)
C. tropicalis 2
C. glabrata 2
Candida not specified 7
Saccharomyces cerevisiae 1
Aspergillus spp.a 2 (10)
A. fumigatus 1
A. niger 1
Candida and Aspergillus spp.a 2 (10)
BMI body mass index, CVVH, ICU intensive care unit
a Mixed infection (Candida and Aspergillus)
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for a healthy 70-kg patient) [24] and the central V was
higher than in ICU with severe peritonitis, sepsis or burn
injuries [27–29] but very similar to ICU patients on CVVH
(22.5 L for a 70-kg patient) [26]. IIV on V1 was 73% CV in
our cohort and thereby two- to ten-fold higher compared
with other studies (8–38% CV) [24, 26, 29]. One expla-
nation could be that healthy volunteers and subjects on
CVVH are more homogenous populations, in which less
variability is observed, while our cohort consisted of ICU
patients with and without CVVH. The estimated IIV may
also have been inflated by one influential individual (BW
134 kg) who seems to be responsible for the improved
model fit when including IIV on V1. V2 was lower in our
Table 2 Pharmacokinetic parameter estimates of the final model and bootstrap analysis
Parameter Parameter estimates [RSE] (shrinkage) Bootstrap results parameter estimates (n = 841)a
Mean (95% CI) [RSE]
CL (L/h)b 1.10 [8%] 1.10 (0.92–1.32) [8.8%]
V1 (L)
b 17.6 [14%] 16.8 (12.53–21.54) [12.7%]
Q (L/h)b 0.363 [20%] 0.363 (0.30–3.82) [26.2%]
V2 (L)
b 3.63 [8%] 3.85 (3.20–7.77) [30.9%]
IIV CL (CV%) 40.1 [23.2%] (1.2%) 38.5 (28–47) [23%]
IIV V1 (CV%) 73.2 [62.7%] (41%) 72.1 (32–119) [53%]
IOV V2 (CV%) 37.0 [77.5%] (25–70%) 35.8 (14–60) [60%]
Proportional residual error 17% [24%] 17% (14–20) [20%]
CI confidence interval, CL clearance, CV coefficient of variation, IIV inter-individual variability, IOV inter-occasion variability, Q inter-com-
partmental clearance, RSE root square error (based on covariance step in NONMEM), V1 volume of distribution of compartment 1, V2 volume of
distribution of compartment 2
a Based on 841/1000 successfully terminated runs (minimisation successful and no boundaries)
b Parameters allometrically scaled to a body weight of 70 kg
Fig. 1 Area under the concentration–time curve (AUC) over 24 h on
day 14 based on Monte-Carlo simulations. The horizontal line
represents the AUC over 24 h for healthy volunteers. Licensed
regimens, I 100 mg daily (QD) and II 100 mg QD followed by
200 mg QD from day 5. Alternative regimens, III a 200-mg loading
dose followed by 100 mg maintenance; IV a 200-mg loading dose
followed by 150 mg maintenance; and V 200 mg QD
Fig. 2 Predicted target attainment at day 3 vs. minimal inhibitory
concentration (MIC) for all five simulated regimens based on a
clinical target area under the concentration–time curve over 24 h/MIC
ratio of C3000 (valid for all Candida spp.). Bars represent the wild-
type population distribution of Candida albicans for micafungin, as
gathered from [22]
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analysis but the total V (V1 ? V2) was comparable to other
pharmacokinetics. [26, 29]
BW was a priory added in the model on CL and V1 in
agreement with physiological plausibility and based on
previous work. [15–18, 26, 29]. It remains a matter of
debate whether one should estimate or fix the allometric
exponents. One group empirically estimated this for
micafungin [29] while another one fixed it [26]. For illus-
tration purposes, we have estimated the allometric expo-
nent of BW to CL, which was 1.26 and this did not
significantly improve the model fit (DOFV -2.97); 1.26 is
very different from what is physiologically plausible and
from the results of another group (0.59) [29]. Based on our
data (n = 20 patients), the true exponent is not identifiable
and using an empirical estimate would not allow for
extrapolation beyond our dataset.
Although not present in our cohort, in the case of
morbidly obese, critically ill patients, BW may not be the
ideal parameter to relate size to pharmacokinetics. Other
weight-derived parameters such as fat-free mass could be
alternative descriptors to explain the variability in PK
parameters in this subpopulation [30]. As micafungin has a
relative low V, only a small fraction is metabolised and
kidney function does not play an important role [3, 26].
BW is assumed to adequately describe the relationship
between body size and the PK parameters for the normal
weight ICU patients [3].
We found an important IOV on V, which means that V
may change considerably from day to day within one
patient. While our data also supported the addition of IOV
on CL, we considered IOV on V more physiologically
plausible, as we observed important fluctuations in peak
concentrations of micafungin. Day-to-day fluctuations in V
may be explained by haemodynamic changes including
fluid retention or fluid loss as result of a capillary leak,
which may occur in ICU patients [31, 32]. Moreover,
including IOV on both CL and V1 resulted in an uniden-
tifiable model with parameter correlation and including
both was, therefore, not considered. A study among ten
ICU patients on CVVH found an IOV on V1 and V2 of
27–28% CV, which was lower compared with our cohort
(37% CV) [26]. This difference might be explained by the
difference in clinical condition: patients on CVVH might
be haemodynamically more stable and controlled in terms
of fluid retention and diuresis than ICU patients not on
CVVH. This is reflected in the lower IOV of V1.
As referenced, we have now conducted several popu-
lation PK studies of echinocandins in ICU patients. We
observed some differences between the various
echinocandins. Unlike caspofungin with identical CL and
V in critically ill patients compared with healthy volun-
teers, micafungin showed a higher CL (1.10 L/h compared
with 0.55 L/h) and a higher V (21.2 L compared with
13.9 L for V1 and V2 together) in ICU patients [33].
Anidulafungin showed similar changes in CL when com-
paring critically ill patients with healthy volunteers, while
V was equal in both populations [34]. It remains unclear
Fig. 3 Predicted target attainment at day 3 vs. minimal inhibitory
concentration (MIC) for all five simulated regimens based on a
clinical target area under the concentration–time curve over 24 h/MIC
ratio of C5000 (valid for non-Candida parapsilosis spp.). Bars
represent the wild-type population distribution of Candida albicans
for micafungin, as gathered from [22]
Table 3 Cumulative fraction of the predicted PTA for Candida
albicans and non-C. parapsilosis based on the five different simulated
regimens
Cumulative fraction of the
predicted PTA (%)
AUC/MIC[3000
Cumulative fraction of the
predicted PTA (%) AUC/MIC
[5000
Regimen Day 3 Day 14 Day 3 Day 14
I 79 83 53 58
II 79 97 53 90
III 81 83 57 58
IV 91 94 76 80
V 95 97 86 90
Licensed regimens, (I) 100 mg QD and (II) 100 mg QD followed by
200 mg QD from day 5. Alternative regimens, (III) a 200-mg loading
dose followed by 100 mg maintenance; (IV) a 200-mg loading dose
followed by 150 mg maintenance; and (V) 200 mg QD
AUC area under the concentration–time curve, MIC minimum inhi-
bitory concentration, PTA probability of target attainment, QD daily
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why micafungin pharmacokinetics changes but caspo-
fungin pharmacokinetics is less affected by critical illness,
as we could not find any covariates, apart from BW, to
explain the variability in PK parameters. Covariates might
be obscured owing to the overall high variability in phar-
macokinetics among ICU patients, caused by a mixture of
factors (e.g. systemic inflammatory response, capillary
leak, protein-binding capacity) [35]. Combining datasets
and thereby increasing sample size may help to further
clarify this.
Our results confirm that the exposure (AUC0–24h) in the
ICU population after 100 mg QD is much lower than the
exposure with the same dose in healthy volunteers, which
is consistent with our previous analysis [7]. Increasing the
maintenance dose in ICU patients to 150 mg led to equal
exposure compared with healthy volunteers. When the
labeled 200 mg is chosen, this would lead to higher
exposure compared with healthy volunteers. Theoretically,
lower exposure risks decreased efficacy and it is known
that AUC is inversely linked to disease outcome when
exposed to pathogens with increasing MICs [9].
We have simulated the licensed regimens, as well as
alternative regimens. Based on our simulations and the
PTA assessment with the 3000 target (all Candida spp.),
the majority (83%) of the ICU population is treated ade-
quately with the currently licensed 100-mg maintenance
dose. Higher maintenance doses of 200 mg QD are only
required in the case of infections with species with
decreased susceptibility. However, based on the 5000 tar-
get (non-C. parapsilosis), the majority of the population
may benefit from a dose increase to 200 mg QD as a result
of low target attainment with the 100 mg QD (62% attains
the 5000 target with MIC 0.016). Although this can be
considered a worst-case scenario, no susceptibility profiles
are available upon the start of therapy, for which a 200-mg
dose QD may be beneficial until the results of the micro-
biology are available. If the MIC allows, one can scale
down to 100 mg QD. This should be evaluated prospec-
tively. Alternatively, a 200-mg loading dose for all ICU
patients can be beneficial, to achieve early adequate
exposure (also shown in Fig. S3). Especially given the high
IOV of V1, it is of great importance to adequate saturate all
compartments with micafungin.
Our results are comparable to previous work [26, 29]
and confirm that species with attenuated MICs may benefit
from higher maintenance doses. It should be noted that PK-
PD targets vary considerable among Candida species and
the target greatly influences the outcome: the PTA
decreases when the target increases [8]. Thus, correct
selection of the target is crucial for adequate interpretation
of the PTA. When starting therapy, the MIC is often
unknown. With this in mind, our results encourage the
prospective evaluation of a higher initial dose (e.g. 200 mg
maintenance), as it may have the potential to decrease the
rate of patients not attaining the target. This should be
evaluated for superiority in a prospective trial.
In addition, modelling and simulation are always
associated with uncertainty, further challenging the
interpretation of the estimated PTA. We therefore took
parameter uncertainty into account when performing
Monte-Carlo simulations of micafungin in ICU patients,
subsequently used for the PTA predictions. The variabil-
ity in exposure (Fig. 1) is a combination of parameter
uncertainty and variability in BW. Although this uncer-
tainty is taken into account in the PTA predictions, Fig. 2
does not show any variability as it was based on the
proportion of patients attending the PK target. Another
approach could be to perform multiple simulations (e.g.
1000 times) using parameter precision information from a
bootstrap analysis and calculate confidence intervals
around the PTA [36].
The current work is inevitably associated with some
limitations, which are discussed below. The first relates to
the high IIV on V1, which may have been inflated by an
influential individual with a BW of 134 kg, the highest BW
of the cohort. However, the inclusion of the parameter
improved the model fit to the data significantly and it is not
surprising to encounter deviating individuals in heteroge-
neous ICU cohorts. We therefore decided to retain this
individual in the cohort and proceed with IIV on V1, but at
the same time underline the uncertainty in the estimated
value of this parameter. The second limitation relates to the
fact we did not have information on the unbound mica-
fungin concentrations. As micafungin is highly protein
bound, fluctuations in albumin (likely to occur among ICU
patients) may influence total concentrations and thereby the
PTA. This might have led to an underestimation rather than
an overestimation of the PTA.
5 Conclusion
In summary, a population PK model of micafungin in ICU
patients was developed and used to assess the PTA for
licensed as well as alternative dosing regimens. We are the
first to incorporate uncertainty in parameter estimates in
Monte-Carlo simulations. We conclude that the majority of
the population is adequately treated with a 100-mg main-
tenance dose based on the 3000 target but not with the 5000
target. Candida species with higher MICs require higher
maintenance doses of 200 mg. As it takes several days
before microbiology results are obtained, starting with a
higher initial dose (e.g. 200 mg QD) may result in a
superior treatment outcome. Although this alternative
dosing strategy may be off-label, our findings encourage its
investigation.
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